AMENDMENT

It is respectfully requested that the application be amended without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A topical pharmaceutical composition comprising ketamine in a tolerance-attenuating dosage, morphine and a pharmaceutically acceptable topical excipient effectively delivering the ketamine and morphine to local peripheral receptors and not to central receptors, wherein the dosage of ketamine is within a tolerance-attenuating range sufficient to yield a dose-lowering effect on the morphine such that the concentration of morphine necessary to provide effective analgesia is within a range of about 1.0 to about 10% by weight of the composition.

2-6. (Cancelled)

7. (Original) The topical pharmaceutical composition according to claim 1, further comprising a local anesthetic.

8. (Original) The topical pharmaceutical composition according to claim 7, wherein the local anesthetic is selected from the group consisting of lidocaine, bupivacaine, mepivacaine, ropivacaine, tetracaine and benzocaine.

9. (Previously Presented) A method of providing peripheral analgesia and not central or systemic analgesia to a mammal comprising topically administering a tolerance-attenuating dose of ketamine prior to, concurrently with, or following topically administering morphine, wherein the morphine and ketamine function through local peripheral receptors and not central receptors, wherein the administration is by topical application of an aqueous solution, gel, lotion, ointment, cream or spray and the dosage of ketamine is within a tolerance-attenuating range sufficient to yield a dose-lowering effect on the morphine such that the concentration of

morphine necessary to provide effective analgesia is within a range of about 1.0 to about 10% by weight of the composition.

10-13. (Cancelled)

14. (Previously Presented) The method according to claim 9, wherein ketamine is administered in a dose of about 0.1 % to about 5%, by weight, of total weight of ketamine and morphine.

15. (Currently Amended) A method of providing tolerance attenuating analgesia to a mammal with pre-existing tolerance to an analgesic comprising topically administering a tolerance-attenuating dose of ketamine concurrently or following topically administering morphine, wherein the morphine and ketamine function through local peripheral receptors and not central receptors, wherein the administration is by topical application of an aqueous solution, gel, lotion, ointment, cream or spray and the dosage of ketamine is within a tolerance-attenuating range sufficient to yield a dose-lowering effect on the morphine such that the concentration of analgesic necessary to provide effective analgesia is within a range of about 1.0 to about 10% by weight of the composition.

16-18. (Cancelled)

19. (Previously Presented) The topical pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable topical excipient is in the form of an aqueous excipient.

20. (Previously Presented) The topical pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable topical excipient is in the form of a gel excipient.

21. (Previously Presented) The method according to claim 9, wherein the administration is by topical application of an aqueous solution.

22. (Previously Presented) The method according to claim 15, wherein the administration is by topical application of an aqueous solution.

23.-26. (Cancelled)

27. (Currently Amended) A topical pharmaceutical composition comprising ketamine and morphine and a topical excipient effectively delivering the ketamine and morphine to local peripheral opiate receptors and not to central opiate receptors and wherein the excipient is condensation products of an alkylene oxide with fatty acids, aloe vera, DMSO, lecithin, lecithine base, or propylene glycol, and the dosage of ketamine is within a tolerance-attenuating range sufficient to yield a dose-lowering effect on the morphine such that the concentration of morphine necessary to provide effective analgesia is within a range of about 1.0 to about 10% by weight of the composition.

28. (Previously Presented) The topical pharmaceutical composition according to claim 27, further comprising a local anesthetic.

29. (Previously Presented) The topical pharmaceutical composition according to claim 28, wherein the local anesthetic is selected from the group consisting of lidocaine, bupivacaine, mepivacaine, ropivacaine, tetracaine and benzocaine.

30. (Cancelled)